Pfizer says vax for 5-11 year olds is safe and effective

In a highly anticipated announcement, Pfizer said on Monday a Phase 2/3 trial showed its Covid-19 vaccine was safe and generated a “robust” antibody response in children ages 5 to 11.

These are the first such results released for this age group for a US Covid-19 vaccine, and the data has not yet been peer-reviewed or published. Pfizer said it plans to submit to the US Food and Drug Administration for emergency use authorization soon. FDA officials have said that once data is submitted, the agency could authorize a vaccine for younger children in a matter of weeks.

The trial included 2,268 participants ages 5 to 11 and used a two-dose regimen of the vaccine administered 21 days apart. This trial used a 10-microgram dose — smaller than the 30-microgram dose that has been used for those 12 and older.

We are primarily funded by readers. Please subscribe and donate to support us!

“The 10 microgram dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to 11 years of age,” Pfizer said in a news release.

www.msn.com/en-us/health/medical/covid-19-vaccine-for-5-to-11-year-olds-is-safe-and-shows-robust-antibody-response-pfizer-says/ar-AAOD99w

Views:

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.